clinical trial · NCT07708181
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·phase2·not yet recruiting·n = 200
Gout ArthritisSSGJ-613 100 mg Q12WSSGJ-613 200 mg Q12WSSGJ-613 100 mg Q4WColchicine 0.5 mg
brief summary
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
started
Aug 2, 2026
primary completion
Aug 11, 2027
completion
Apr 19, 2028
last updated
Jul 20, 2026
official title
A Phase 2, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol